UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma
Shots:
- UroGen presented sub-analysis data from the real-world patient cohort review of Jelmyto (mitomycin) for pyelocalyceal solution at AUA 2024
- The low-grade Ta UTUC patients responding completely to induction therapy (n=53) had RFS rate of 86% at 24mos., irrespective of initial disease characteristics or usage for chemoablation vs post-endoscopic ablation. Those who received maintenance therapy (30% complete responders) had an RFS of 100% vs 61% for those who did not at 24mos.
- Investigators are currently recruiting patients in the prospective & retrospective uTRACT Registry assessing Jelmyto's potential for treating UTUC to record data in a large-scale, standardized manner for reporting patient outcomes
Ref: UroGen Pharma | Image: UroGen Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
